Skip to content
2000
Volume 4, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Introduction

HCV infection has led to high mortality and morbidity rates, highlighting the need for immediate measures to contain and eradicate infection while providing optimal care to infected patients who may present with various comorbidities. Pharmacists play a crucial role in managing drug-drug interactions that exist with medications to treat comorbidities and DAAs.

Method

A prospective cohort study was conducted among patients who received DAAs at 17 Ministry of Health (MOH) facilities. Following the screening, the obtainment of consent, and recruitment, details on demographic background, comorbidities, type of HCV infection, and treatment, along with medication reconciliation, were performed. A simple and multiple logistic regression was performed to determine factors associated with DDI occurrence.

Results and Discussion

A total of 404 patients were recruited. Out of 291 patients (72%) who received at least one co-medication, drug-drug interactions (DDIs) were reported in 174 patients (59.8%). DDI with Amlodipine was the most common (n=77, 36.2%). Out of 213 DDI detected, 208 (97.7%) were categorized as moderate interaction. The number of comorbidities and the number of co-medications were significantly associated with the occurrence of DDIs

Conclusion

Pharmacists play a key role in managing drug-drug interactions in HCV patients. With the high incidence of interaction observed in this study, it is crucial to manage individually since comorbidities vary with patients. As such, eradication of HCV infection can be undertaken with less opportunity of treatment failure.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906348476250526115431
2025-07-31
2026-02-19

  • From This Site

    /content/journals/ijghd/10.2174/0126662906348476250526115431
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Updated recommendations of treatment of adolescents and children with chronic HCV infection. In:HCV Simplified Service Delivery and Diagnostics.Geneva, SwitzerlandWorld Heath Organizations202218
     [Google Scholar]
  2. Global health sector on, respectively. In:HIV Viral Hepatitis and Sexually Transmitted for the Period-2023.Geneva, SwitzerlandWorld Heath Organizations202215
     [Google Scholar]
  3. MangiaA. ScaglioneF. ToniuttoP. PirisiM. CoppolaN. PerriD.G. NietoA.G. CalabreseS. HernandezC. PerroneV. EspostiD.L. FagiuoliS. Drug–drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: Insights from a real-world study.Int. J. Environ. Res. Public Health20211813714410.3390/ijerph18137144 34281080
     [Google Scholar]
  4. ZorattiM.J. SiddiquaA. MorassutR.E. ZeraatkarD. ChouR. HoltenV.J. XieF. DruytsE. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis.EClin Med.20201810023710.1016/j.eclinm.2019.12.007 31922124
     [Google Scholar]
  5. Andrieux-MeyerI. TanS.S. ThanprasertsukS. SalvadoriN. MenétreyC. SimonF. CresseyT.R. SaidH.R.H.M. HassanM.R.A. OmarH. TeeH.P. ChanW.K. KumarS. ThongsawatS. ThetketK. AvihingsanonA. KhemnarkS. YerlyS. Ngo-Giang-HuongN. SivaS. SwansonA. GoyalV. BompartF. PécoulB. MuradS. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): Interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.Lancet Gastroenterol. Hepatol.20216644845810.1016/S2468‑1253(21)00031‑5 33865507
     [Google Scholar]
  6. CoghlanM. O’LearyA. MelanophyG. BerginC. NorrisS. Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.Int. J. Clin. Pharm.20194151227123810.1007/s11096‑019‑00876‑6 31297695
     [Google Scholar]
  7. Protocol Hepatitis Medication Therapy Adherence Clinic Protocol Hepatitis Medication Therapy Adherence Clinic, 2nd Ed; Centre, Putrajaya: Centre, Putrajaya201819
     [Google Scholar]
  8. YamamotoH. IkesueH. IkemuraM. MiuraR. FujitaK. ChungH. SuginoshitaY. InokumaT. HashidaT. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: A retrospective analysis.J. Pharm. Health Care Sci.2018411710.1186/s40780‑018‑0113‑3 30026959
     [Google Scholar]
  9. KhullarV. FirpiR.J. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.World J. Hepatol.20157141843185510.4254/wjh.v7.i14.1843 26207166
     [Google Scholar]
  10. HudsonB. WalkerA.J. IrvingW.L. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.J. Med. Virol.201789122158216410.1002/jmv.24848 28480974
     [Google Scholar]
  11. MohamedN.A. RashidZ.Z. WongK.K. A, S.A.; Rahman, M.M. Hepatitis C genotype and associated risks factors of patients at university Kebangsaan Malaysia medical centre.Pak. J. Med. Sci.20132951142114610.12669/pjms.295.3610 24353708
     [Google Scholar]
  12. SandmannL. SchulteB. MannsM.P. MaasoumyB. Treatment of chronic hepatitis C: Efficacy, side effects and complications.Visc. Med.201935316117010.1159/000500963
     [Google Scholar]
  13. RidruejoE. PeresonM.J. FlichmanD.M. LelloD.F.A. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions.World J. Hepatol.202113910691078 34630875
     [Google Scholar]
  14. MartínezD.C.V.M. PwuRF. ShabaruddinH. F Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.Front. Public Health202111111456010.3389/fpubh.2023.1114560
     [Google Scholar]
  15. CooperC.L. GalanakisC. DonelleJ. KwongJ. BoydR. BoucherL. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: A retrospective cohort study.BMC Infect. Dis.201919171210.1186/s12879‑019‑4315‑6
     [Google Scholar]
  16. SorianoV. BerenguerJ. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients.Curr. Opin. HIV AIDS201510530931510.1097/COH.0000000000000175 26132342
     [Google Scholar]
  17. KondiliL.A. GaetaG.B. IeluzziD. ZignegoA.L. MontiM. GoriA. SoriaA. RaimondoG. FilomiaR. LeoD.A. IannoneA. MassariM. CorsiniR. GulminettiR. CominiG.A. ToniuttoP. DissegnaD. RussoF.P. ZanettoA. RumiM.G. BrancaccioG. DanieliE. BrunettoM.R. WeimerL.E. QuarantaM.G. VellaS. PuotiM. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.PLoS One2017122017215910.1371/journal.pone.0172159 28245248
     [Google Scholar]
  18. CostaD.RB CostaMB LongoL MiottoDE DellaviaGH MichalczukMT Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction.Preval Comorbidit Comedicat2021162e024576710.1371/journal.pone.0245767
     [Google Scholar]
  19. VutienP. High rates of comorbidities and polypharmacy in patient with chronic hepatitis C (CHC) in real-world setting: A consequence of an aging population.Hepatology201460889A942A
     [Google Scholar]
  20. NéantN. SolasC. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection.Int. J. Antimicrob. Agents202056110557110.1016/j.ijantimicag.2018.10.014 30394302
     [Google Scholar]
  21. WhiteleyD. SpeakmanE. ElliottL. DavidsonK. HamiltonE. JarvisH. QuinnM. FlowersP. Provider‐related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis.J. Viral Hepat.202128352853710.1111/jvh.13443 33215781
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906348476250526115431
Loading

  • Article Type:     Research Article
Keyword(s): co-medications; comorbidities; drug-drug interaction; HCV patients; hepatitis C infection; Pharmacists

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test